6872 — TenNor Therapeutics (Suzhou) Share Price
Last trade - 00:00- HK$5.32bn
- HK$4.56bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.93 | ||
| Price to Tang. Book | 7.21 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -19.57% | ||
| Return on Equity | -42.55% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TenNor Therapeutics (Suzhou) Ltd is a China-based company primarily engaged in the discovery, development and commercialization of differentiated therapies. The main products include Rifasutenizol (TNP-2198), a novel molecular entity drug candidate for the treatment of H. pylori infection, Rifaquizinone (TNP-2092) injection, a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections, TNP-2092 oral, a multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism, diabetic foot infections, the chemical series of small molecules TNBi-1, multi-targeting drug conjugate series TNBi-2, and the chemical series of dual-functional small molecules TNBm-1. The Company focuses on the fields of bacterial infections and metabolic-related diseases.
Directors
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- February 25th, 2013
- Public Since
- May 22nd, 2026
- No. of Employees
- 53
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 52,328,926
- Address
- SUZHOU, 215123
- Web
- http://www.tennortherapeutics.com
- Phone
- +86 51286861990
- Auditors
- PricewaterhouseCoopers
Latest News for 6872
Upcoming Events for 6872
TenNor Therapeutics (Suzhou) Ltd Extraordinary Shareholders Meeting
Similar to 6872
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 05:42 UTC, shares in TenNor Therapeutics (Suzhou) are trading at HK$101.70. This share price information is delayed by 15 minutes.
Shares in TenNor Therapeutics (Suzhou) last closed at HK$101.70 and the price had moved by over the past 365 days. In terms of relative price strength the TenNor Therapeutics (Suzhou) share price has matched the FTSE Developed Asia Pacific Index by over the past year.
There is no consensus recommendation for this security.
Find out moreTenNor Therapeutics (Suzhou) does not currently pay a dividend.
TenNor Therapeutics (Suzhou) does not currently pay a dividend.
TenNor Therapeutics (Suzhou) does not currently pay a dividend.
To buy shares in TenNor Therapeutics (Suzhou) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$101.70, shares in TenNor Therapeutics (Suzhou) had a market capitalisation of HK$5.32bn.
Here are the trading details for TenNor Therapeutics (Suzhou):
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 6872
Based on an overall assessment of its quality, value and momentum TenNor Therapeutics (Suzhou) is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TenNor Therapeutics (Suzhou). Over the past six months, its share price has matched the FTSE Developed Asia Pacific Index by .
As of the last closing price of HK$101.70, shares in TenNor Therapeutics (Suzhou) were trading -43.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The TenNor Therapeutics (Suzhou) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$101.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on TenNor Therapeutics (Suzhou)'s directors